Daiichi Sankyo

AstraZeneca plc (NYSE: AZN) and partner DAIICHI SANKYO/S ADR (OTC: DSNKY) announced positive news Thursday on their HER-2 targeting antibody drug conjugate, or ADC. This should come as a relief for the U.K. pharma giant, which recently flunked a late-stage non-small cell lung cancer study....

The first Phase 3 trials for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)'s Syk inhibitor are expected to be announced in August as many investors and analysts prepare for the results. H.C. Wrainwright's Positive Take On Phase 3 H.C. Wainwright & Co's Shaunak Deepak initiated Rigel...